InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Telomir Pharmaceuticals, Inc.

TELO Clue Score37
United States Fiscal year ends December CIK 0001971532
$1.12 -2.61% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.12 −41.97% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 9 Feb 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Net income
Fiscal year 2022Net income−0.9EPS, diluted−0.03Fiscal year 2023Net income−13.1EPS, diluted0.48Fiscal year 2024Net income−16.5EPS, diluted−0.56 −216.7%Fiscal year 2025Net income−10.4EPS, diluted−0.33
FY2022FY2023FY2024FY2025
Net income −0.9 −13.1 −16.5 −10.4
Growth
EPS, diluted −0.03 0.48 −0.56 −0.33
Growth −216.7%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow−0.5Fiscal year 2023Operating cash flow−3.9Fiscal year 2024Operating cash flow−5.1Fiscal year 2025Operating cash flow−3.7
FY2022FY2023FY2024FY2025
Operating cash flow −0.5 −3.9 −5.1 −3.7

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Shareholders’ equity−0.9Fiscal year 2023Shareholders’ equity3.4Fiscal year 2024Cash1.3Shareholders’ equity0.6Fiscal year 2025Shareholders’ equity5.9
FY2022FY2023FY2024FY2025
Cash n/a n/a 1.3 n/a
Shareholders’ equity −0.9 3.4 0.6 5.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −380.2% −2,571.0% −176.1%
−1,752.8% −273.8% −1,248.7% −141.8%
Balance and payout
2,023.4% 28.0% 51.4% 19.5%